VKH
TVTX icon

Virtu KCG Holdings’s Travere Therapeutics TVTX Stock Holding History

Virtu KCG Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,507
Closed -$129K – 3886
2014
Q4 		$129K Buy
+10,507
New +$109K ﹤0.01% 3107

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu KCG Holdings's TVTX Position: Q1 2015 in Review

Virtu KCG Holdings sold out of Travere Therapeutics (TVTX) in Q1 2015, closing a stake of 10,507 shares — an estimated $129K sold.

Virtu KCG Holdings first reported a position in TVTX in Q4 2014 and held it in 1 quarter. The position peaked at $129K in Q4 2014. 81 funds tracked by Wall St. Rank hold TVTX as of Q1 2015.

  • Virtu KCG Holdings reported no remaining Travere Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Virtu KCG Holdings sold 10,507 Travere Therapeutics shares in Q1 2015, an estimated $129K.
  • Virtu KCG Holdings first reported a position in Travere Therapeutics in Q4 2014 and held it in 1 quarter.
  • Virtu KCG Holdings's Travere Therapeutics position peaked at $129K in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2015.

Based on Virtu KCG Holdings's 13F filing for Q1 2015, filed 15 May 2015.